Large-scale testing (Phase 3)Study completedNCT03546842
What this trial is testing
Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)
Who this might be right for
Papillomavirus InfectionsUterine Cervical NeoplasmsVulvar Neoplasms+3 more
Merck Sharp & Dohme LLC 201